Merck Reports Encouraging Results from Trial

Merck Reports Encouraging Results from Trial

Merck & Company shares were up over 2% pre-market Tuesday after the drug maker reported positive results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of doravirine, the company’s investigational treatment for HIV-1 infection. At 48 weeks, the study showed that a once-daily single tablet, fixed-dose combination of doravirine (DOR), lamivudine (3TC), and tenofovir disoproxil fumarate (TDF) met its primary efficacy endpoint. Data […]

Read More ˃